Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences Inc. (NASDAQ: DTIL) on November 10, 2022, reporting events that occurred on November 5, 2022. The filing addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
On November 5, 2022, Dr. Raymond Schinazi resigned from the Board of Directors with immediate effect. His resignation also included his roles as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee and Science and Technology Committee. Dr. Schinazi will continue to serve on the Company's Scientific Advisory Board.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) regarding the Board change. No financial guidance, outlook, or new risk factors were disclosed in this specific document.
Key Facts for Investors
- Dr. Raymond Schinazi resigned from the Board of Directors and all associated committee roles effective November 5, 2022.
- Dr. Schinazi remains on the Scientific Advisory Board.
- The filing does not provide updated financial performance metrics or liquidity data.
- Investors should review the referenced press release (Exhibit 99.1) for additional context on the resignation.